CHOROIDAL THICKNESS and CHORIORETINAL ATROPHY in MYOPIC CHOROIDAL NEOVASCULARIZATION with ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY

Ji Hwan Lee, Sung Chul Lee, Seo Hee Kim, Hyoung Jun Koh, Sung Soo Kim, Suk Ho Byeon, Christopher Seungkyu Lee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: This study investigated factors associated with chorioretinal atrophy (CRA) progression in myopic choroidal neovascularization (CNV) after anti-vascular endothelial growth factor therapy. Methods: Fifty eyes of 50 treatment-naive patients with myopic CNV who underwent anti-vascular endothelial growth factor monotherapy with at least 2 years of follow-up data were included. The cumulative occurrence of CRA progression was assessed using a Kaplan-Meier analysis. Demographic and clinical characteristics including macular choroidal thickness in various areas were compared between patients with and without CRA progression. Results: The mean age was 52.34 years. A mean of 4.84 anti-vascular endothelial growth factor injections were performed over the mean follow-up duration of 44.6 months. Eventually, 15 eyes (30%) developed CRA progression. The estimated occurrence of CRA progression was 10% at 1 year, 19.1% at 2 years, 23.6% at 3 and 4 years, and 35.4% at 5 years. Chorioretinal atrophy progression was associated with a subfoveal CNV location (P = 0.029) and thinner subfoveal choroid in relation to the inferior choroid at 3 mm (P = 0.008). Visual improvement was only significant in eyes without CRA progression at 1 year, 2 years, and at the final visit. Conclusion: Chorioretinal atrophy progression was associated with a poor long-term prognosis. Relative thinning of the subfoveal choroid about the inferior choroid and subfoveal CNV location may predispose eyes with myopic CNV to develop CRA progression after anti-vascular endothelial growth factor therapy.

Original languageEnglish
Pages (from-to)1516-1522
Number of pages7
JournalRetina
Volume37
Issue number8
DOIs
Publication statusPublished - 2017 Aug 1

Fingerprint

Choroidal Neovascularization
Vascular Endothelial Growth Factor A
Atrophy
Choroid
Therapeutics
Kaplan-Meier Estimate
Demography
Injections

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Lee, Ji Hwan ; Lee, Sung Chul ; Kim, Seo Hee ; Koh, Hyoung Jun ; Kim, Sung Soo ; Byeon, Suk Ho ; Lee, Christopher Seungkyu. / CHOROIDAL THICKNESS and CHORIORETINAL ATROPHY in MYOPIC CHOROIDAL NEOVASCULARIZATION with ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. In: Retina. 2017 ; Vol. 37, No. 8. pp. 1516-1522.
@article{ca692726c40e46059fb33c854e174644,
title = "CHOROIDAL THICKNESS and CHORIORETINAL ATROPHY in MYOPIC CHOROIDAL NEOVASCULARIZATION with ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY",
abstract = "Purpose: This study investigated factors associated with chorioretinal atrophy (CRA) progression in myopic choroidal neovascularization (CNV) after anti-vascular endothelial growth factor therapy. Methods: Fifty eyes of 50 treatment-naive patients with myopic CNV who underwent anti-vascular endothelial growth factor monotherapy with at least 2 years of follow-up data were included. The cumulative occurrence of CRA progression was assessed using a Kaplan-Meier analysis. Demographic and clinical characteristics including macular choroidal thickness in various areas were compared between patients with and without CRA progression. Results: The mean age was 52.34 years. A mean of 4.84 anti-vascular endothelial growth factor injections were performed over the mean follow-up duration of 44.6 months. Eventually, 15 eyes (30{\%}) developed CRA progression. The estimated occurrence of CRA progression was 10{\%} at 1 year, 19.1{\%} at 2 years, 23.6{\%} at 3 and 4 years, and 35.4{\%} at 5 years. Chorioretinal atrophy progression was associated with a subfoveal CNV location (P = 0.029) and thinner subfoveal choroid in relation to the inferior choroid at 3 mm (P = 0.008). Visual improvement was only significant in eyes without CRA progression at 1 year, 2 years, and at the final visit. Conclusion: Chorioretinal atrophy progression was associated with a poor long-term prognosis. Relative thinning of the subfoveal choroid about the inferior choroid and subfoveal CNV location may predispose eyes with myopic CNV to develop CRA progression after anti-vascular endothelial growth factor therapy.",
author = "Lee, {Ji Hwan} and Lee, {Sung Chul} and Kim, {Seo Hee} and Koh, {Hyoung Jun} and Kim, {Sung Soo} and Byeon, {Suk Ho} and Lee, {Christopher Seungkyu}",
year = "2017",
month = "8",
day = "1",
doi = "10.1097/IAE.0000000000001384",
language = "English",
volume = "37",
pages = "1516--1522",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

CHOROIDAL THICKNESS and CHORIORETINAL ATROPHY in MYOPIC CHOROIDAL NEOVASCULARIZATION with ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. / Lee, Ji Hwan; Lee, Sung Chul; Kim, Seo Hee; Koh, Hyoung Jun; Kim, Sung Soo; Byeon, Suk Ho; Lee, Christopher Seungkyu.

In: Retina, Vol. 37, No. 8, 01.08.2017, p. 1516-1522.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CHOROIDAL THICKNESS and CHORIORETINAL ATROPHY in MYOPIC CHOROIDAL NEOVASCULARIZATION with ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY

AU - Lee, Ji Hwan

AU - Lee, Sung Chul

AU - Kim, Seo Hee

AU - Koh, Hyoung Jun

AU - Kim, Sung Soo

AU - Byeon, Suk Ho

AU - Lee, Christopher Seungkyu

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Purpose: This study investigated factors associated with chorioretinal atrophy (CRA) progression in myopic choroidal neovascularization (CNV) after anti-vascular endothelial growth factor therapy. Methods: Fifty eyes of 50 treatment-naive patients with myopic CNV who underwent anti-vascular endothelial growth factor monotherapy with at least 2 years of follow-up data were included. The cumulative occurrence of CRA progression was assessed using a Kaplan-Meier analysis. Demographic and clinical characteristics including macular choroidal thickness in various areas were compared between patients with and without CRA progression. Results: The mean age was 52.34 years. A mean of 4.84 anti-vascular endothelial growth factor injections were performed over the mean follow-up duration of 44.6 months. Eventually, 15 eyes (30%) developed CRA progression. The estimated occurrence of CRA progression was 10% at 1 year, 19.1% at 2 years, 23.6% at 3 and 4 years, and 35.4% at 5 years. Chorioretinal atrophy progression was associated with a subfoveal CNV location (P = 0.029) and thinner subfoveal choroid in relation to the inferior choroid at 3 mm (P = 0.008). Visual improvement was only significant in eyes without CRA progression at 1 year, 2 years, and at the final visit. Conclusion: Chorioretinal atrophy progression was associated with a poor long-term prognosis. Relative thinning of the subfoveal choroid about the inferior choroid and subfoveal CNV location may predispose eyes with myopic CNV to develop CRA progression after anti-vascular endothelial growth factor therapy.

AB - Purpose: This study investigated factors associated with chorioretinal atrophy (CRA) progression in myopic choroidal neovascularization (CNV) after anti-vascular endothelial growth factor therapy. Methods: Fifty eyes of 50 treatment-naive patients with myopic CNV who underwent anti-vascular endothelial growth factor monotherapy with at least 2 years of follow-up data were included. The cumulative occurrence of CRA progression was assessed using a Kaplan-Meier analysis. Demographic and clinical characteristics including macular choroidal thickness in various areas were compared between patients with and without CRA progression. Results: The mean age was 52.34 years. A mean of 4.84 anti-vascular endothelial growth factor injections were performed over the mean follow-up duration of 44.6 months. Eventually, 15 eyes (30%) developed CRA progression. The estimated occurrence of CRA progression was 10% at 1 year, 19.1% at 2 years, 23.6% at 3 and 4 years, and 35.4% at 5 years. Chorioretinal atrophy progression was associated with a subfoveal CNV location (P = 0.029) and thinner subfoveal choroid in relation to the inferior choroid at 3 mm (P = 0.008). Visual improvement was only significant in eyes without CRA progression at 1 year, 2 years, and at the final visit. Conclusion: Chorioretinal atrophy progression was associated with a poor long-term prognosis. Relative thinning of the subfoveal choroid about the inferior choroid and subfoveal CNV location may predispose eyes with myopic CNV to develop CRA progression after anti-vascular endothelial growth factor therapy.

UR - http://www.scopus.com/inward/record.url?scp=84992740362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992740362&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000001384

DO - 10.1097/IAE.0000000000001384

M3 - Article

C2 - 27798519

AN - SCOPUS:84992740362

VL - 37

SP - 1516

EP - 1522

JO - Retina

JF - Retina

SN - 0275-004X

IS - 8

ER -